Image via WikipediaADT for Prostate Cancer Not Associated With CV Mortality
20.12.11
Phase II Study of Bolus 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel as First-Line Therapy for Advanced Gastric Cancer | DocGuide
Phase II Study of Bolus 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel as First-Line Therapy for Advanced Gastric Cancer | DocGuide
FLTAX
paclitaxel 80 mg/m(2) as a 1-hour infusion, followed by 5-FU 600 mg/m(2) as a bolus infusion and L-leucovorin 250 mg/m(2) as a 2-hour infusion on days 1, 8 and 15. Treatment cycles were repeated every 28 days.
FLTAX
paclitaxel 80 mg/m(2) as a 1-hour infusion, followed by 5-FU 600 mg/m(2) as a bolus infusion and L-leucovorin 250 mg/m(2) as a 2-hour infusion on days 1, 8 and 15. Treatment cycles were repeated every 28 days.
15.12.11
LATESTBreastCancer Blog: BRCA Mutation Breast Cancer News: The 2011 San Antonio Breast Cancer Symposium and Beyond
LATESTBreastCancer Blog: BRCA Mutation Breast Cancer News: The 2011 San Antonio Breast Cancer Symposium and Beyond
...BRCA 1 or BRCA 2 gene mutation have a higher risk of developing cancer in the opposite breast than non-carriers. Medical News Today and MSN/HealthDay covered the Symposium presentation.
The study followed 5,061 women with cancer in one breast for about 8 years. 211 women carried a BRCA 1 or BRCA 2 gene mutation. For women with a BRCA mutation, the 10-year risk of developing cancer in the opposite breast was 17.6 percent, compared to a 6 percent risk for non-carriers.
Age at diagnosis affected risk. For BRCA carriers first diagnosed before the age of 40, the 10-year risk was 26 percent. For those diagnosed between 40 and 50, the risk was 11.6 percent.
Triple-negative status also mattered. Triple-negative BRCA carriers had a 10-year risk of 18.9 percent, compared to 11.2 percent for BRCA carriers who were not triple-negative.....
...BRCA 1 or BRCA 2 gene mutation have a higher risk of developing cancer in the opposite breast than non-carriers. Medical News Today and MSN/HealthDay covered the Symposium presentation.
The study followed 5,061 women with cancer in one breast for about 8 years. 211 women carried a BRCA 1 or BRCA 2 gene mutation. For women with a BRCA mutation, the 10-year risk of developing cancer in the opposite breast was 17.6 percent, compared to a 6 percent risk for non-carriers.
Age at diagnosis affected risk. For BRCA carriers first diagnosed before the age of 40, the 10-year risk was 26 percent. For those diagnosed between 40 and 50, the risk was 11.6 percent.
Triple-negative status also mattered. Triple-negative BRCA carriers had a 10-year risk of 18.9 percent, compared to 11.2 percent for BRCA carriers who were not triple-negative.....
11.12.11
Another Major Trial Challenges Axillary Dissection Practice
Another Major Trial Challenges Axillary Dissection Practice
IBCSG Trial 23-01
A randomized trial of axillary dissection vs. no axillary dissection for patients with clinically node negative breast cancer and micrometastases in the sentinel node
In certain women with early-stage breast cancer and positive nodes, sentinel lymph node dissection (SLND) does not result in inferior survival, compared with axillary lymph node dissection (ALND)
The women in the study all had clinical T1/T2 invasive breast cancer and 1 or 2 sentinel lymph nodes (SLNs).
IBCSG Trial 23-01
A randomized trial of axillary dissection vs. no axillary dissection for patients with clinically node negative breast cancer and micrometastases in the sentinel node
In certain women with early-stage breast cancer and positive nodes, sentinel lymph node dissection (SLND) does not result in inferior survival, compared with axillary lymph node dissection (ALND)
The women in the study all had clinical T1/T2 invasive breast cancer and 1 or 2 sentinel lymph nodes (SLNs).
Midstream Chemo Switch May Improve Breast Cancer Survival
Midstream Chemo Switch May Improve Breast Cancer Survival
GEPAR-TRIO
GEPAR-TRIO
Changing chemotherapy regimens midstream on the basis of individual patient responses to the first 2 cycles pays off with improved overall survival (OS) and disease-free survival (DFS) rates for patients with luminal-type breast cancers, according to a study reported here at the 34th Annual San Antonio Breast Cancer Symposium (SABCS).
But patients with HER2-positive or triple-negative (lacking HER2, estrogen, and progesterone receptors) tumors did not have a benefit from response-guided therapy, reported Gunther von Minckwitz, MD, PhD, professor and senior physician at the Center for Gynecology and Obstetrics at the University of Frankfurt in Frankfurt, Germany, on behalf of colleagues in the GEPAR-TRIO (GErman Pre-operative Adriamycin and Docetaxel) trial.
The trial also showed a disconnect between treatment effects and complete responses on pathology (pCR) in some disease subtypes,.......
Antiestrogen Combo New Standard for Metastatic Breast Cancer?
Antiestrogen Combo New Standard for Metastatic Breast Cancer?
Women with metastatic breast cancer have extended survival if their physicians simply combine anastrazole (Arimidex, AstraZeneca) and fulvestrant (Faslodex, AstraZeneca), a study presented here at the 34th Annual San Antonio Breast Cancer Symposium shows.
Women taking the 2 drugs in combination lived more than 6 months longer than women who took the drugs sequentially, according to the researchers who presented their findings....
'New Standard of Care' for Some Advanced Breast Cancers
'New Standard of Care' for Some Advanced Breast Cancers
Adding everolimus (Afinitor, Novartis), a mammalian target of rapamycin (mTOR) inhibitor, to exemestane (Aromasin) significantly improved progression-free survival of postmenopausal women with advanced estrogen receptor–positive breast cancer vs exemestane alone, according to updated findings from a randomized trial reported here at the 34th Annual San Antonio Breast Cancer Symposium....
BOLERO-2
Among 724 women, median progression-free survival (PFS) with the addition of everolimus to exemestane was 7.4 months, compared with 3.2 months for exemestane alone (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.36 - 0.53; P < .001), reported Gabriel N. Hortobagyi, MD, on behalf of investigators in the BOLERO-2 (Breast Cancer Trials of Oral Everolimus-2) trial.
'Huge' Development in HER2+ Metastatic Breast Cancer
'Huge' Development in HER2+ Metastatic Breast Cancer
The combination of trastuzumab (Herceptin, Roche/Genentech) and the experimental agent pertuzumab (Roche/Genentech) significantly prolonged progression-free survival (PFS) by 6 months compared with trastuzumab alone, according to a new study of HER2-positive metastatic breast cancer in the first-line setting.
One Third of Cancers Caused by Lifestyle Factors
One Third of Cancers Caused by Lifestyle Factors
One third of all cancers are caused by 4 common lifestyle factors — tobacco, diet, alcohol, and obesity.
This finding comes from a detailed review of lifestyle and environmental factors. Researchers calculated the fraction of cancers that can be attributed to each of these factors. The huge study was published as a supplement to the December issue of the British Journal of Cancer...
Přihlásit se k odběru:
Příspěvky (Atom)